PTH 1-34
Phase 3Small molecule
PTH 1-34 is one of 52 small molecule programs targeting Hypoparathyroidism. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
172 competitors in Osteoporosis
#DrugCompanyPhaseTrials
1Boniva
CConrado Roberto Hoffmann Filho
Phase 3
Actonel
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
One-Alpha
RochePhase 3
Livial
PfizerPhase 3
Depo-Provera
Eli LillyPhase 3
Tymlos
RRadius Health, Inc.
Phase 3
Glucophage
EMD SeronoPhase 3
Oxycodone IR
Johnson & JohnsonPhase 3
Bazedoxifene Acetate
PfizerPhase 3
Tapentadol IR
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypoparathyroidism1 trial
Effects of PTH Replacement on Bone in Hypoparathyroidism
Terminated·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 3·NCT00395538·46 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PTH 1-34. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details